Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Capitalism and greed gave Britain its vaccine success, PM Johnson says

Tue, 23rd Mar 2021 21:51

* Johnson tries to row back from gaffe on greed

* Praises capitalism in vaccine lead

* UK state money developed the Oxford vaccine

* Communist China moved fast to develop a vaccine
(Adds context on Oxford vaccine)

By Costas Pitas

LONDON, March 24 (Reuters) - Capitalism and greed gave
Britain its success in vaccinating its population, Prime
Minister Boris Johnson told lawmakers in a closed meeting, a
remark that could rile up Brussels at a time when Britain faces
an EU threat to block vaccine imports.

"The reason we have the vaccine success is because of
capitalism, because of greed my friends," The Sun newspaper
quoted Johnson as telling Conservative lawmakers on a Zoom
meeting on Tuesday evening.

Johnson then tried to row back and said: "Actually I regret
saying it" and asked lawmakers repeatedly to "forget I said
that".

Britain has so far mounted the fastest COVID-19 vaccine
programme of any big country. But it now finds its programme
threatened by the EU, which has been far slower in rolling out
vaccines and faces a third wave of infections.

The European Commission is expected on Wednesday to extend
powers to block exports, a move that could hit supply of doses
bound for Britain. Johnson's remarks come after a week in which
British ministers have tried to calm the row.

Downing Street declined to comment on Johnson's remarks when
contacted by Reuters, but unidentified sources gave the BBC a
bizarre array of explanations.

The greed comment, according to the BBC's political editor
Laura Kuenssberg, was apparently a joke about one of his cabinet
colleagues, Chief Whip Mark Spencer, who was gobbling a cheese
and pickle sandwich while the prime minister spoke.

Johnson, Home Secretary Priti Patel said, was talking about
the success of pharmaceutical companies in developing a vaccine
shot in record time.

"Clearly the prime minister was actually referring to the
work that has taken place with pharmaceutical companies and how
we have led the way really in this vaccine development," said
Patel, who was not in the meeting.

Britain was one of several countries that developed a
COVID-19 vaccine shot in record time: the shot developed by
Oxford University and AstraZeneca was approved for use
on Dec. 30 by the British medicines regulator.

The British government helped fund the research, and
AstraZeneca has promised to market it on a not-for-profit basis.

Other vaccines around the world have been developed with
state funding, from Communist China and former communist Russia
to the capitalist United States.
(Reporting by Costas Pitas and Guy Faulconbridge; Editing by
Steve Orlofsky, Rosalba O'Brien, Kate Holton and Peter Graff)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.